Liraglutide Effect on Weight and A1C in Patients with Type 2 Diabetes Mellitus: Real-World Data from a Single Tertiary Care Center in Saudi Arabia

Objective: This retrospective study aimed to determine the effect of liraglutide on weight and HbA1c levels in patients with type 2 diabetes mellitus (T2DM) in Saudi Arabia. The present investigation was carried out at a medical facility located in the Kingdom of Saudi Arabia. Materials and Methods: A retrospective analysis was conducted on the clinical records of 290 patients who were diagnosed with T2DM and were above 18 years of age. These patients were administered liraglutide for a minimum of 6 months. The dataset comprised various parameters such as the duration of diabetes, duration of liraglutide therapy, weight, and multiple biochemical markers such as HbA1c and low-density lipoprotein cholesterol levels. These parameters were measured both before and after the administration of liraglutide therapy. Results: The primary metrics evaluated in this study were alterations in body weight and levels of glycated hemoglobin (HbA1c). Over the 24-month observational period, significant reductions in body mass index (38.6 kg/m(2) to 37 kg/m(2)), body weight (99.3 kg to 96 kg), and HbA1c levels (8.9% to 7.8%) (all P < 0.01) were seen. Conclusion: Liraglutide reduced HbA1c levels and weight and affected multiple metabolic markers in patients with T2DM in a real-world setting in Saudi Arabia.